Clay Siegall

Dec 06, 2010 at 08:00 | Source: Reuters
A pivotal trial of Seattle Genetics' experimental cancer-targeting antibody for patients with Hodgkin's lymphoma found that more than a third of them achieved complete remission of their cancer.

Photos »

Remission rate 34% for Seattle Genetics drug
Follow us on
Available On